These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15928379)

  • 1. Use of rituximab in two unusual antibody-mediated autoimmune disorders.
    Adler M; Soliotis F; Thakrar S; Stratton R
    J R Soc Med; 2005 Jun; 98(6):271-2. PubMed ID: 15928379
    [No Abstract]   [Full Text] [Related]  

  • 2. [New treatments for systemic diseases].
    Bader-Meunier B; Willems M
    Arch Pediatr; 2006 Jun; 13(6):596-8. PubMed ID: 16690273
    [No Abstract]   [Full Text] [Related]  

  • 3. [CD20 antibody for the treatment of systemic autoimmune diseases].
    Tanaka Y
    Nihon Rinsho; 2005 May; 63 Suppl 5():728-33. PubMed ID: 15954437
    [No Abstract]   [Full Text] [Related]  

  • 4. [Role of biologic therapy in systemic autoimmune diseases].
    Espinosa G; Cervera R
    Med Clin (Barc); 2007 Mar; 128(12):456-7. PubMed ID: 17408539
    [No Abstract]   [Full Text] [Related]  

  • 5. Inflammation: Rituximab in ANCA vasculitis and lupus: bittersweet results.
    Bosch X
    Nat Rev Nephrol; 2010 Mar; 6(3):137-9. PubMed ID: 20186231
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment with rituximab of autoimmune disease: results from AADEA's registry].
    Callejas Rubio JL; Camps MT; García-Hernández F;
    Med Clin (Barc); 2008 Jan; 130(2):79. PubMed ID: 18221681
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of systemic lupus erythematosus with epratuzumab.
    Traczewski P; Rudnicka L
    Br J Clin Pharmacol; 2011 Feb; 71(2):175-82. PubMed ID: 21219397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential utility of B cell-directed biologic therapy in autoimmune diseases.
    Arkfeld DG
    Rheumatol Int; 2008 Jan; 28(3):205-15. PubMed ID: 17957371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
    Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
    Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cell depletion in autoimmune disease.
    Gorman C; Leandro M; Isenberg D
    Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S17-21. PubMed ID: 15180893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).
    Scheinberg M; Hamerschlak N; Kutner JM; Ribeiro AA; Ferreira E; Goldenberg J; Kiss MH; Chahade WH
    Clin Exp Rheumatol; 2006; 24(1):65-9. PubMed ID: 16539821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of severe juvenile microscopic polyangiitis with rituximab.
    Brunner J; Freund M; Prelog M; Binder E; Sailer-Hoeck M; Jungraithmayr T; Huemer C; Sergi C; Zimmerhackl LB
    Clin Rheumatol; 2009 Aug; 28(8):997-9. PubMed ID: 19390907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.
    Kazkaz H; Isenberg D
    Curr Opin Pharmacol; 2004 Aug; 4(4):398-402. PubMed ID: 15251135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular targeting in autoimmunity.
    Rogers JL; Serafin DS; Timoshchenko RG; Tarrant TK
    Curr Allergy Asthma Rep; 2012 Dec; 12(6):495-510. PubMed ID: 23054625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).
    Arzoo K; Sadeghi S; Liebman HA
    Ann Rheum Dis; 2002 Oct; 61(10):922-4. PubMed ID: 12228164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab.
    Doan T; Massarotti E
    Drugs Today (Barc); 2005 Dec; 41(12):785-97. PubMed ID: 16474854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
    Tanaka Y
    Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab.
    Saigal K; Valencia IC; Cohen J; Kerdel FA
    J Am Acad Dermatol; 2003 Nov; 49(5 Suppl):S283-5. PubMed ID: 14576655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in treatment-resistant autoimmune blistering skin disorders.
    Schmidt E; Bröcker EB; Goebeler M
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):56-64. PubMed ID: 18270859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLE - Rituximab in lupus.
    Eisenberg R
    Arthritis Res Ther; 2003; 5(4):157-9. PubMed ID: 12823844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.